All News

Merck held a conference call Thursday morning to discuss its Q1 2022 earnings. The company reported a 50% growth in revenue, increasing its worldwide sales to $15.9 billion.
Chimera’s research comes largely from its GOLD platform, a technology that reprograms RNA gene regulation circuits to alter chimeric antigen receptors (CAR) on T cells.
Sio Gene has terminated its licensing deal with the UMass to develop and commercialize two gene therapy product candidates to focus on more potentially profitable projects.
Amgen held its earnings conference call on Wednesday for Q1 of 2022. Most notably, the company provided updates on its ongoing litigation with the Internal Revenue Service.
The Q1 results for Voxzogo gave BioMarin the confidence to raise its 2022 full-year guidance to between $100 million to $125 million (net product revenue) for the drug.
Bryostatin-1 increases antigen expression on the surface of cancer cells, enabling them to be seen and killed by IO agents.
Rising awareness about hepatitis symptoms and growing need for early diagnosis through public education and increasing occurrence of hepatitis across the globe are fueling global market growth.
Zentalis Pharmaceuticals announced that Pfizer made a $25 million equity investment in the company.
Exogene nets $2 million to propel the development of its AI platform for T-cell receptor discovery and Healome spins out to deploy a ‘pro-healing’ platform with a focus on ocular surface diseases.
FDA
AviadoBio is celebrating orphan drug designations from both the U.S. FDA and the European Commission for AVB-101, a gene therapy intended to treat frontotemporal dementia (FTD).
BeiGene’s candidate drug tislelizumab for cancer succeeded in meeting the primary endpoint of overall survival in a global Phase III trial. Learn more about it here.
Weeks after Gilead Sciences raised concern over counterfeit HIV drugs, Johnson & Johnson has taken similar action against the distribution of counterfeit prescription drugs.
Microbiologics, Inc. the foremost provider of biomaterials and contract microbiology research services, is pleased to announce the acquisition of Cryologics
Cytovia Holdings, a biopharma company focused on natural killer (NK) cells, merged with special purpose acquisition company (SPAC) Isleworth Healthcare Acquisition Corp. to go public.
The U.S. Congress is calling for the coronavirus management plan to deliberate on the timeline for the approval and release of vaccines for children under 5 years old.
David Sabatini, who was ousted last year by the Whitehead Institute over allegations of sexual harassment, may have found a new home at the NYU Grossman School of Medicine.
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
It can be difficult to prioritize getting organized, but taking precautionary steps can actually save you time in the long run. To help, here are nine organization strategies for busy professionals.
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.